NextFin News - The National Health and Medical Research Council (NHMRC) and all Australian state and territory health departments have officially endorsed the InFORMed Participant Information and Consent Form (PICF) template, marking a structural shift in how clinical research is conducted across the country. The endorsement, finalized in February 2026, aims to replace the increasingly legalistic and dense documents that have long served as a bottleneck for medical innovation and patient recruitment.
The move addresses a persistent friction point in the Australian health sector: the complexity of consent. Research from the University of Sydney and other institutions has historically shown that nearly 44% of Australians possess literacy levels below the grade 11 or 12 threshold required to navigate traditional PICFs. In some cases, consent forms for anaesthesia and cardiovascular trials reached lengths of 35 pages, with readability scores far exceeding the NHMRC’s recommended Grade 8 level. This complexity has not only deterred potential participants but has also increased the administrative burden on research sites and sponsors.
Dr. Lisa Eckstein, Director of CT:IQ and an ethics specialist for Bellberry, has been a central figure in this transition. Eckstein, who also holds an adjunct position at the University of Tasmania, has long advocated for participant-centered research frameworks. Under her leadership, CT:IQ—a non-profit dedicated to clinical trial efficiency—developed the InFORMed template to prioritize "layered consent." This approach moves technical and optional details to secondary sections, ensuring that the primary document focuses strictly on the information essential for a participant’s decision-making. While Eckstein’s position is widely respected within the clinical trials community, her focus on simplification is sometimes viewed with caution by legal departments at major pharmaceutical sponsors who prioritize liability protection over brevity.
The endorsement is not merely a change in formatting but a strategic attempt to bolster Australia’s competitive position in the global clinical trials market. By streamlining the ethics approval process through a nationally recognized template, the NHMRC expects to reduce the time-to-market for new therapies. The template incorporates multimedia aids, such as videos and voiceovers, and includes a National Data Sharing Statement developed in partnership with the Australian Research Data Commons (ARDC). This specific addition addresses the growing legal complexity surrounding the future use of biological samples and digital health data.
However, the transition to the InFORMed template is not without its skeptics. Some industry observers note that while the NHMRC "endorses" the form, its adoption remains voluntary for many private research entities. There is a risk that without mandatory enforcement, the "legalistic creep" that expanded these forms over the last decade could persist as risk-averse institutional review boards continue to demand exhaustive disclosures. Furthermore, the effectiveness of the template relies heavily on researchers’ willingness to engage in early consumer consultation, a process that requires additional time and resources that smaller research units may lack.
The financial implications of this shift are significant for the Australian medical research sector, which contributes billions to the national economy. Reducing the "consent barrier" is expected to improve recruitment rates among diverse populations, particularly those with lower health literacy who were previously marginalized by complex documentation. As the NHMRC integrates these links into its official ethical guidelines, the focus now shifts to implementation. The success of the InFORMed project will ultimately be measured by whether it can maintain its simplified structure against the inevitable pressure of evolving privacy regulations and international compliance standards.
Explore more exclusive insights at nextfin.ai.
